TECH

Bio-Techne Corporation

$72.82

-0.01%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.

Source: Yahoo Finance
AI summary

Price & performance

1M+0.5%
3M+1.1%
YTD+22.4%
1Y+17.9%
52-week range—
Beta1.12
Full chart and returns against a benchmark

Q-Score

66/ 100

Quality against peers; 50 is the peer median.

Growth53
Risk73
Performance49
Valuation55
Profitability74
Leverage70
Sentiment21
Every score and metric

News sentiment

Open News

Latest results · FY 2026

Revenue$1.2B-0.4%
Net income$181.9M+147.8%
Net margin15.0%+8.9 pts
Historical fundamentals

Revenue exposure

48%of revenue from outside the US
United States52%
Other countries24%
China9%
Regions, segments, customers and suppliers

Valuation

TECHIndustryP/E66.5289.69P/S9.3111.88EV/EBITDA33.4467.10P/B5.286.22PEG0.554.02
Dividend yield0.44%
Every valuation metric

Earnings

Nov 9next report
EPS estimate$0.45
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate